WebTrametinib is a small molecule that selectively inhibits MEK1 and MEK2. 102 In Phase I and II trials, trametinib caused tumor regression and stabilization of disease in patients with BRAF V600E/K mutation. 103,104 In the METRIC trial, patients (n=322) with stage IIIC or stage IV BRAF V600E/K-mutated melanoma were randomly assigned 2:1 to receive … WebMay 29, 2013 · The median time to onset of cardiomyopathy in patients treated with trametinib was 63 days (range 16 to 156 days); cardiomyopathy was identified within the first month of treatment with trametinib ...
Cardiotoxicity mechanisms of the combination of BRAF …
WebCardiotoxicity may manifest as asymptomatic reduction in left ventricular ejection fraction (LVEF), arrhythmia, ... In both the dabrafenib-trametinib and monotherapy groups, … WebIf a dose of trametinib is missed, when dabrafenib is given in combination with trametinib, the dose of trametinib should only be taken if it is more than 12 hours until the next scheduled dose. Dose modification Two dabrafenib capsule strengths, 50 mg and 75 mg, are available to effectively manage dose modification requirements. fezolinetant 作用機序
3678-Melanoma adjuvant daBRAFEnib and tRAMEtinib eviQ
WebCardiotoxicity may manifest as asymptomatic reduction in left ventricular ejection fraction (LVEF), arrhythmia, ... After a median follow up of 44 months in the dabrafenib and … WebGSK announced today that the FDA has approved both TAFINLAR® (dabrafenib) and MEKINIST™ (trametinib). ... (7/211) of trametinib. Cardiomyopathy resolved in 10 of these 14 (71%) patients. Across clinical trials of trametinib at the recommended dose (n=329), 11% of patients developed evidence of cardiomyopathy ... WebNICE TA321. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (October 2014) Recommended with restrictions. NICE TA396. … fezon